The Thermo Fisher Scientific Proteomics Facility for Disease Target Discovery has begun operations at the Gladstone Institutes, as part of a collaboration between Thermo Fisher, Gladstone, the University of California, San Francisco, and QB3, to accelerate targeted proteomics research using advanced mass spectrometry techniques.
The facility, directed by Nevan J. Krogan, Ph.D., senior investigator at the Gladstone Institutes, professor of cellular and molecular pharmacology at UCSF, and director of the UCSF division of the life science research institute and startup accelerator QB3, will provide scientists from Gladstone, UCSF, and QB3 with advanced mass spec techniques to characterize protein dynamics in complex biological systems. The technologies will enable scientists to acquire unprecedented knowledge about the interactions between genes and the proteins they produce, and help facilitate solutions to unanswered biomedical problems, according to Dr. Krogan.
Among the activities to take place at the facility are the creation of high-resolution protein-protein interaction maps and advanced protein characterization, genome-directed proteomic screening and selection, and ultra-sensitive, quantitative analysis of protein abundance, and post-translational modifications.
The facility also will showcase the latest mass spectrometers for detailed biological discovery and quantitation, including the new Orbitrap Fusion Tribrid and TSQ Quantiva Triple Quadrupole LC/MS systems. In addition to enabling research, the Thermo Fisher facility will be a focal point for promoting biological applications of mass spectrometry by hosting an invited lecture series, discussion groups, workshops, and trainings.
